All Vtesse's existing series A investors, including Pfizer and Lundbeck, returned to provide a $17m extension that boosted the round's total to $42m.
US-based rare disease treatment developer Vtesse raised $17m on Monday from investors including pharmaceutical firms Pfizer and Lundbeck to expand its series A round to $42m.
The corporates, which participated through respective investment vehicles Pfizer Venture Investments and Lundbeckfond Ventures, were joined by Alexandria Venture Investments, the venture capital arm of life sciences real estate firm Alexandria Real Estate Equities, New Enterprise Associates and Bay City Capital.
The same five-strong consortium provided the round’s $25m first tranche in January 2015.
…
